
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking, and how infusion of replacement therapy works to achieve normal levels of blood clotting. It also illustrates the clotting factor cascade and highlights the points in the cascade where each type of hemophilia treatment product acts to impact the ability to form blood clots.

In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.

This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been

A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which